Impact of Visceral and Hepatic Fat on Cardiometabolic Health
Tasveer Khawaja1,2, Matthew Nied2, Abigail Wilgor2
1Harrington Heart and Vascular Institute, University Hospitals Cleveland and Case Western Reserve University, Cleveland, OH, USA.
Insights
Visceral fat strongly links to heart disease, while hepatic fat
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Disorders
Background:
- Body fat distribution significantly impacts cardiometabolic health.
- Visceral and hepatic fat depots are key areas of concern in obesity.
Purpose of the Study:
- To review the impact of visceral and hepatic fat on cardiometabolic outcomes.
- To highlight current and emerging interventions for managing ectopic fat.
Main Methods:
- Review of epidemiologic studies and recent clinical evidence.
- Analysis of pharmacologic and lifestyle interventions.
- Evaluation of surgical and emerging therapeutic strategies.
Main Results:
- Visceral fat is clearly associated with cardiovascular disease.
- Hepatic fat's link to cardiovascular disease is less definitive.
- Sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing ectopic fat and cardiometabolic risk.
Conclusions:
- Visceral fat has established cardiometabolic consequences.
- Hepatic fat's role requires further clarification.
- Lifestyle, pharmacologic, and surgical interventions, alongside emerging therapies, are crucial for managing body fat distribution and cardiometabolic risk.
Purpose Of Review:
Body fat distribution plays a significant role in the cardiometabolic consequences of obesity. We review the impact of visceral and hepatic fat and highlight important interventions.
Recent Findings:
Several epidemiologic studies have established a clear association between visceral fat and cardiovascular disease. The association between hepatic fat and cardiovascular disease is less clear with discordant results. Novel evidence demonstrates sodium glucose co-transporter-2 (SGLT2) inhibitors facilitate modest weight loss and reductions in ectopic fat depots in patient with type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor agonists have been associated with decreased visceral/hepatic fat and reductions in MACE in populations with type 2 diabetes and with overweight/obesity. Clear associations between visceral fat and cardiometabolic outcomes have been established, whereas the impact of hepatic fat remains less clear. Lifestyle modification and pharmacologic interventions remain the initial therapies, while surgical intervention is associated with improved long-term outcomes. Emerging therapies have demonstrated a profound impact on body fat distribution and cardiometabolic risk.
More Related Videos
Related Concept Videos
Cholesterol: Significance and Regulation
Considering cholesterol and...
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Hypodermis
Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Obesity
Lipid-derived Compounds in the Human Body
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...


